Hospital
Community Health Association
Community Health Association was paid $15.27M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoCOMMUNITY HEALTH ASSOCIATION
RIPLEY, WV 25271
RIPLEY, WV 25271
33aNPI1649277476assigned 07/07/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$15.27M
24GClaims253,022
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in West Virginia
Rank by total paid#1 of 5
Median peer was paid$6.61M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,922 | $3.14M | |
| 2019 | 21,948 | $1.74M | |
| 2020 | 42,968 | $3.02M | |
| 2021 | 49,366 | $2.63M | |
| 2022 | 29,495 | $1.86M | |
| 2023 | 40,626 | $1.66M | |
| 2024incomplete | 27,697 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 17,356 | 14,382 | $2.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 10,276 | 8,093 | $2.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.8% | 4,900 | 3,592 | $1.35M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.0% | 878 | 777 | $604K |
| 80053 | Comprehensive metabolic panel | 3.9% | 14,871 | 12,483 | $603K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 15,897 | 12,904 | $448K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 578 | 491 | $365K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 1,378 | 1,215 | $322K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 24,933 | 19,389 | $250K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 3,496 | 2,656 | $243K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 6,196 | 5,570 | $241K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 3,577 | 3,214 | $234K |
165 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 5,238 | $233K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 3,015 | $226K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 4,049 | $222K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 3,448 | $208K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 5,275 | $189K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,831 | $166K |
| 80061 | Lipid panel | 1.1% | 4,777 | $161K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 980 | $157K |
| 83605 | 1.0% | 4,151 | $154K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,294 | $144K |
| 84484 | <1% | 3,334 | $141K | |
| 81001 | <1% | 6,427 | $141K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,987 | $129K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,206 | $127K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,052 | $122K |
| 83690 | <1% | 3,284 | $108K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,165 | $103K |
| 84439 | <1% | 2,703 | $100K | |
| 85027 | <1% | 4,283 | $99K | |
| 83735 | <1% | 3,782 | $98K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,735 | $94K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,634 | $94K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 993 | $92K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,225 | $90K |
| 87040 | <1% | 1,753 | $88K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,430 | $81K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,801 | $77K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 358 | $75K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,890 | $74K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,950 | $70K |
| 72110 | <1% | 573 | $68K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,734 | $63K |
| 73562 | <1% | 857 | $62K | |
| 73630 | <1% | 813 | $61K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,570 | $56K |
| 81003 | <1% | 2,148 | $52K | |
| J2704 | Injection, propofol, 10 mg | <1% | 777 | $51K |
| 73610 | <1% | 642 | $50K | |
| 87186 | <1% | 1,810 | $48K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,026 | $47K |
| 85610 | <1% | 2,873 | $47K | |
| 83880 | <1% | 1,140 | $46K | |
| 73130 | <1% | 490 | $41K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 995 | $39K |
| 81025 | <1% | 1,203 | $39K | |
| 96376 | <1% | 563 | $38K | |
| 87070 | <1% | 944 | $36K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 660 | $36K |
| 87077 | <1% | 1,050 | $36K | |
| 73030 | <1% | 470 | $35K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 244 | $35K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 5,527 | $34K |
| 85730 | <1% | 1,644 | $33K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 516 | $32K |
| 85379 | <1% | 564 | $32K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,537 | $31K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 572 | $30K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 101 | $29K |
| 73110 | <1% | 367 | $29K | |
| 97035 | <1% | 864 | $28K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,183 | $26K |
| 80076 | <1% | 327 | $24K | |
| 84703 | <1% | 388 | $24K | |
| 86140 | <1% | 939 | $23K | |
| 82550 | <1% | 930 | $23K | |
| 97161 | <1% | 323 | $22K | |
| 82962 | <1% | 939 | $22K | |
| 87081 | <1% | 1,357 | $22K | |
| 82805 | <1% | 686 | $20K | |
| 87430 | <1% | 462 | $19K | |
| 80305 | <1% | 351 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 235 | $16K |
| 87631 | <1% | 99 | $15K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 101 | $14K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 42 | $14K |
| 82043 | <1% | 772 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,230 | $13K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 166 | $13K |
| 74022 | <1% | 160 | $12K | |
| 84145 | <1% | 477 | $12K | |
| 95117 | <1% | 1,185 | $12K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 248 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 330 | $10K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,958 | $8K |
| 82248 | <1% | 821 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 31 | $8K |
| 88142 | <1% | 193 | $8K | |
| 87205 | <1% | 398 | $8K | |
| 87807 | <1% | 124 | $7K | |
| 87088 | <1% | 583 | $7K | |
| 82607 | <1% | 211 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 117 | $7K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 586 | $7K |
| 80306 | <1% | 108 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,354 | $6K |
| 74019 | <1% | 81 | $6K | |
| 74018 | <1% | 116 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 34 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 217 | $5K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 151 | $5K |
| 73502 | <1% | 88 | $5K | |
| 87563 | <1% | 127 | $5K | |
| 82553 | <1% | 81 | $5K | |
| 87147 | <1% | 120 | $5K | |
| 36600 | <1% | 305 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 466 | $5K |
| 20553 | <1% | 16 | $4K | |
| 72100 | <1% | 88 | $4K | |
| 85651 | <1% | 342 | $4K | |
| 80320 | <1% | 32 | $4K | |
| 0099U | <1% | 32 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 167 | $4K |
| 85007 | <1% | 114 | $4K | |
| 72050 | <1% | 30 | $4K | |
| 82150 | <1% | 107 | $3K | |
| 76536 | <1% | 28 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 110 | $3K |
| 82570 | <1% | 254 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 72 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 23 | $3K |
| 96127 | <1% | 100 | $3K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 104 | $3K |
| 86677 | <1% | 81 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 519 | $3K |
| 20610 | <1% | 76 | $2K | |
| 72072 | <1% | 28 | $2K | |
| 83540 | <1% | 113 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 35 | $2K |
| 87075 | <1% | 86 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $2K |
| 80050 | General health panel | <1% | 29 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 44 | $2K |
| J3490 | Unclassified drugs | <1% | 1,279 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 23 | $1K |
| 82728 | <1% | 42 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 183 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 18 | $1K |
| 73080 | <1% | 14 | $953.58 | |
| 86803 | <1% | 33 | $939.06 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 258 | $925.93 |
| 97162 | <1% | 12 | $906.48 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 30 | $850.53 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 68 | $805.67 |
| 82140 | <1% | 29 | $785.15 | |
| 84436 | <1% | 19 | $734.51 | |
| 84466 | <1% | 30 | $720.07 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 22 | $635.19 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 53 | $608.94 |
| 80143 | <1% | 13 | $428.76 | |
| 83050 | <1% | 34 | $418.24 | |
| 82746 | <1% | 12 | $356.39 | |
| 90715 | <1% | 26 | $352.19 | |
| 11721 | <1% | 23 | $344.82 | |
| 86901 | <1% | 12 | $304.02 | |
| 86038 | <1% | 12 | $302.17 | |
| 86900 | <1% | 12 | $273.11 | |
| 80179 | <1% | 13 | $266.36 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 62 | $201.12 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19 | $194.36 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 41 | $165.88 |
| 90656 | <1% | 12 | $58.87 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 20 | $37.66 |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | 0% | 42 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCOY, STEPHANIE (PRESIDENT CEO)
| Provider | Location | Paid |
|---|---|---|
| Community Health Association | Ripley, WV | $4.38M |
| Community Health Association | Ripley, WV | $1.04M |
| Community Health Association | Ripley, WV | $292K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.